Retatrutide characterization: structure, charge variants & triple-receptor potency
Retatrutide is a 39-amino-acid triple agonist at GLP-1, GIP and glucagon receptors, built on a GIP-backbone scaffold with Aib2, Aib20 and α-methyl-Leu13, and lipidated with a C20 fatty diacid (eicosanedioic acid) at Lys17. With no pharmacopoeial monograph yet, orthogonal first-principles data carry the full weight of the quality dossier.
What each method answers for retatrutide
Obtain a c(s) sedimentation coefficient distribution under selected formulation and concentration conditions. Report relative signals for resolved groups and compare with SEC when relevant.
Compare far-UV CD spectra and estimate secondary structure where applicable. Near-UV fingerprints and apparent transition temperatures depend on signal quality and interpretable transitions.
Determine apparent pI and relative peak areas for resolvable species. Assigning a peak to a particular charge variant requires a reference material or independent structural evidence.
Report dose–response curves and EC50 separately for GLP-1R / GIPR / GCGR. Relative potency against a reference may be calculated when the comparison criteria for each receptor assay are met.
Retatrutide impurity library
The catalog covers synthesis and degradation-related impurities. Confirm specifications, batch documentation, availability and lead time for the requested item.
- [D-Tyr1]Retatrutide
- [β-Asp9]Retatrutide
- [D-β-Asp15]Retatrutide
- Nε17-[D-γ-Glu2]-Retatrutide
- [γ-Glu24]Retatrutide
- [γ-Glu28]Retatrutide
- [Des-Tyr1]Retatrutide
- [Des-Gln3]Retatrutide
Retatrutide characterization — common questions
How do you characterize retatrutide when no pharmacopoeial monograph exists?+
From first principles: an orthogonal dataset covering aggregation (SV-AUC), conformation (CD), charge heterogeneity (cIEF) and receptor-level potency (reporter bioassay) builds the characterization package aligned with ICH Q6B — independent of any compendial method.
Can you profile triple-receptor potency bias?+
Yes. GLP-1R, GIPR and GCGR CRE-luciferase reporter cell lines are run in parallel; EC50 and relative potency are fitted per receptor, and the cross-receptor activity ratios quantify the triple-agonist bias against a reference standard.
Which retatrutide impurities should be controlled?+
Key classes include D-epimers, β-Asp isomerization at Asp9/Asp15, SPPS deletion and insertion sequences, and γ-Glu linkage isomers such as [γ-Glu24]- and [γ-Glu28]Retatrutide. The catalog lists 118 retatrutide standards. Availability is confirmed by item.
We are early-phase with little material — is the panel feasible?+
Yes. The platform methods are low-consumption and share one sample set; a few milligrams typically cover all four techniques. Method adaptation to a new molecule is part of the free analytical assessment.
Can you support comparability across scale-up batches?+
Yes — side-by-side orthogonal profiles (c(s), CD/Tm, cIEF variant ratios, triple-receptor potency) with quantitative acceptance windows, structured per ICH Q5E.
Developing retatrutide or another triple agonist?
Send us the molecular details — we return a tailored orthogonal characterization plan within 2 business days.